Related Experiment Video
Updated: Feb 5, 2026
10:13
Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
2.9K
[Insulin analogs in 1991].
1Service d'Endocrinologie-Diabétologie-Nutrition, Hôpital Jean-Verdier, Bondy.
Diabete & Metabolisme
|July 1, 1991
Summary
New insulin analogues aim to better mimic natural insulin release after meals, overcoming limitations of current soluble and long-acting insulins for improved diabetes management.
Area of Science:
- Biochemistry and Pharmacology
- Endocrinology
- Drug Development
Context:
- Current insulin therapies struggle to replicate physiological post-prandial insulin profiles.
- Soluble insulin injections and long-acting insulin crystal suspensions have limitations in mimicking natural insulin release and consistent biological activity.
- Development of insulin analogues is crucial for overcoming these therapeutic challenges.
Purpose:
- To evaluate the in vitro characteristics of novel insulin analogues.
- To assess the biological effects of these analogues in animal models.
- To investigate the clinical efficacy and safety of insulin analogues in healthy subjects and diabetic patients.
Summary:
- This study examines insulin analogues designed to improve upon existing insulin formulations.
- The research includes in vitro analysis, animal studies, and clinical trials in humans.
- Focus is placed on analogues with potential for therapeutic application in diabetes management.
- Insulin analogues offer a promising approach to achieving more physiological insulin profiles.
Impact:
- Potential for improved glycemic control in diabetic patients.
- Enhanced simulation of natural insulin secretion patterns.
- Development of more predictable and effective insulin treatments.
- Advancement in the therapeutic landscape for diabetes mellitus.
Related Concept Videos
01:05Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
01:28Insulin: The Receptor and Signaling Pathways
3.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.3K
01:27Insulin Formulations: Types and Delivery
744
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
744
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.4K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.4K
01:16Insulin: Dosing Regimen and Adverse Effects
788
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
788
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K